RxDoctor Payments Data

Benjamin Stein, MD

Orthopaedic Surgery · Washington, DCNPI 1306004858

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (42.4%), royalties or licence payments and consulting fees — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Ortho Solutions Inc at 31.1% of the total.

$12,950in general payments, 2019–2025

Across 94 payments — averaging $137.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ortho Solutions Inc$4K
  • Medical Device Business Services, Inc.$2K
  • Stryker$2K
  • Zimmer Biomet$2K
  • Smith+Nephew$2K
  • Microport Orthopedics Inc$328
  • plus $965 from 18 others

What the payments were for

  • Royalty or licence$3,08624%
  • Consulting fees$2,34018%
  • Travel & lodging$5965%
  • Food & beverage$5,49742%
  • Education$1,43211%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,950 in reported general payments places this provider in the 75th percentile of 46 orthopaedic surgery providers in District of Columbia.

See all orthopaedic surgery providers in District of Columbia

Medicare billing

Part B allowed, 2024
$142,211
Medicare patients
331
Services billed
1,703

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Meloxicam109$240
Oxycodone Hcl28$165
Methylprednisolone17$136
Hydroxyzine Pamoate23$64

Paid to pharmacies, not to this prescriber.

Other orthopaedic surgery in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →